Traduction de «approval applications » (Néerlandais → Français) :

TERMINOLOGIE

extracorporele applicator voor hyperthermiesysteem voor extravasculaire circulatie
applicateur extracorporel de système d’hyperthermie de circulation extravasculaire

handbediende applicator voor brachytherapiesysteem voor oog
applicateur manuel de système de brachythérapie oculaire

applicator voor aneurysmaclip
applicateur de clips d’anévrisme

applicator voor thermisch pulsatiesysteem voor ooglid
applicateur pour système de traitement thermique par impulsions sur les paupières

applicator voor oesofageaal brachytherapiesysteem met op afstand bedienbare afterloading
applicateur de système de brachythérapie pour l’œsophage à chargement différé à distance

intracorporele applicator voor hyperthermiesysteem voor extravasculaire circulatie
applicateur intracorporel de système d’hyperthermie de circulation extravasculaire

handbediende applicator voor oesofageaal brachytherapiesysteem
applicateur manuel de système de brachythérapie pour l’œsophage

applicator voor compressiekousen
enfile-bas de contention

applicator voor dermale anesthesie
applicateur dermique d’anesthésie locale

applicator voor tandheelkundige hars
applicateur de matériau de restauration dentaire

TRADUCTIONS EN CONTEXTE

The commission for the supervision of advertising of medicines for human use dealt with 7 approval applications for radio and television information campaigns
The commission for the supervision of advertising of medicines for human use dealt with 7 approval applications for radio and television information campaigns

The commission for the supervision of advertising of medicines for human use dealt with 61 approval applications for radio/TV advertising during 16 meetings
The commission for the supervision of advertising of medicines for human use dealt with 61 approval applications for radio/TV advertising during 16 meetings

Such risks and uncertainties include, among other things, the uncertainties inherent in research and development; whether and when regulatory authorities in countries where regulatory applications for Prevenar 13 may be pending or may be submitted will approve such applications and their decisions regarding labeling and other matters that could affect its availability or commercial potential; and competitive developments.
This release contains forward-looking information that involves substantial risks and uncertainties regarding Prevenar 13, including its potential benefits; and the success of the AMC project for vaccines. Such risks and uncertainties include, among other things, the uncertainties inherent in research and development; whether and when regulatory authorities in countries where regulatory applications for Prevenar 13 may be pending or may be submitted will approve such applications and their decisions regarding labeling and other matters that could affect its availability or commercial potential; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009, and in its reports on Form 10-Q and Form 8-K.

This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.
Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments.

It is the R&D department’s role to protect the participants in clinical trials by giving scientific advice and evaluating, approving, monitoring and checking applications for clinical research, on the basis of sound scientific knowledge.
It is the R&D department’s role to protect the participants in clinical trials by giving scientific advice and evaluating, approving, monitoring and checking applications for clinical research, on the basis of sound scientific knowledge.